Some of the latest in research on myelodysplastic syndromes (MDS) will be presented at the American Society of Clinical Oncology’s 2010 Annual Meeting, set to kick off June 4 in Chicago. MDS presentations will be held June 5 through the meeting’s second to last day, June 7.

The American Society of Clinical Oncology (ASCO) expects 30,000 cancer specialists from all over the world to attend this year’s meeting.  More than 4,000 presentations will be given. Abstracts for these presentations have…

Oral Clolar (clofarabine) may be an effective treatment for people with higher-risk myelodysplastic syndromes (MDS), according to a Phase 2 clinical trial published recently in the Journal of Clinical Oncology. Out of 22 study participants who had higher-risk MDS, half responded to oral Clolar treatment.

The only use for Clolar approved by the Food and Drug Administration is for children with acute lymphoblastic leukemia that has relapsed or has not responded to treatment. However, recent research has focused on Clolar’s…